Transition to newer clot-busting drug improves patient outcomes and lowers treatment cost

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-09-26 03:30 GMT | Update On 2022-09-26 03:30 GMT

A newer-generation clot-busting drug called Tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a new study published in the American Stroke Association's journal Stroke.

Nearly 800,000 people in the United States have a stroke every year. The vast majority of those strokes (about 87%) are ischemic, meaning they occur when a vessel supplying blood to the brain is obstructed by a blood clot. This can result in a corresponding loss of neurologic function.

Both Tenecteplase and alteplase are federally approved for use in dissolving clots in blocked heart arteries. But the newer drug Tenecteplase is also being used by clinicians, off-label, to treat ischemic strokes, because clinical trials in stroke suggest that it may be at least as good as alteplase and it is easier to administer. Tenecteplase is administered by a single 5 to 10 second intravenous injection. The researchers compared its performance with the standard drug for stroke, alteplase, which is injected over 60 minutes.

For patients who come into the emergency department after a stroke, the study found that the "door-to-needle" time — the time between patients' arrival and the moment they receive treatment — was on average six minutes quicker with Tenecteplase. And for patients who also required a thrombectomy, the surgical removal of a blood clot causing the stroke, Tenecteplase sped up the process of transferring the patient to a thrombectomy-capable stroke center by 25 minutes.

Researchers also saw improvements in clinical outcomes for patients given Tenecteplase, including:

A 5% increase in patients who were able to walk independently at time of hospital discharge to home.

A 4% decrease in occurrences of bad events such as brain hemorrhages, discharge to hospice care or death.

The third major improvement: cost. The research team found that Tenecteplase treatment cost the hospitals about $2,500 less than alteplase per patient.

Reference:

Steven Warach et al,Tenecteplase As Stroke Thrombolytic in Practice,Stroke

Full View

Article Source : American Stroke

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Transition to newer clot-busting drug improves patient outcomes and lowers treatment cost

Similar News

Is Air Pollution Quietly Increasing Brain Tumour Risk? Study Sheds Light

Even Low Lead Exposure May Accelerate Memory Loss in Children: Study Finds

Improved Survival Rates for People with Dementia: Global Study Finds

Is Your Brain Aging Too Fast? New Study Can Tell from One Brain Scan

Even in Your 70s, Your Brain May Be Making New Memory Cells: Study Suggests

New AI Tool Accurately Detects Nine Types of Dementia Using Single Brain Scan: Study Shows

Can Electric Fields Help Heal Spinal Cord Injuries? Study Provides Insights

Simple Blood Test Identifies Alzheimer's Patients at Risk of Faster Decline: Study Shows